%20(2).jpg)
Following IMCAS 2026, which concluded this past Saturday in Paris, Kokuma is proud to officially welcome Dr. Michael Gold as Scientific Advisor.
A globally recognized dermatologist, clinical researcher, and thought leader in aesthetic medicine, Dr. Gold brings more than 30 years of experience translating clinical research into real-world dermatology and aesthetic practice. In his advisory role, he will support Kokuma’s dermatology strategy and clinical development as the company advances its pigmentation and skin tone innovation pipeline.
Reflecting on Kokuma’s clinical work, Dr. Gold highlighted what he sees as a key differentiator in today’s hyperpigmentation landscape:
“What stood out was the consistency of the results. In this first clinical study, all 60 subjects showed improvement in pigmentation and brightness by week eight, across multiple skin types. That level of consistency is particularly meaningful in the hyperpigmentation space.” stated Dr. Michael Gold, Founder and Medical Director of Gold Skin Care Center
This emphasis on consistent outcomes across skin types reinforces Kokuma’s commitment to clinically validated, biotech-driven innovation designed for real-world dermatology and cosmeceutical applications.
In a post-IMCAS expert interview, Dr. Gold shares his perspective on pigmentation innovation, biotech-driven discovery, and the trends shaping dermatology and skincare in the years ahead.
What stood out was the consistency of the results. In this first clinical study, all 60 subjects showed improvement in pigmentation and brightness by week eight, which is quite meaningful in the hyperpigmentation space. The study size is strong for an initial trial, and the inclusion of multiple skin types makes the results highly relevant for real-world dermatology and cosmeceutical applications.
Tonasulike-D shows promise as a safe and effective alternative to traditional agents such as hydroquinone or retinoids. It could be useful for managing melasma, post-inflammatory hyperpigmentation, and uneven pigmentation across different skin types. I also see potential for synergy with in-office dermatology procedures and possibly for long-term maintenance, which remains a challenge in pigmentation care.
Biotech enables faster and more precise innovation. With advances in AI-driven research and new scientific tools, we can better target the biological pathways involved in skin health. At the same time, clinicians and consumers increasingly expect products to be supported by clinical evidence rather than marketing-driven claims.
There is strong demand for evidence-backed, high-performance actives in the cosmeceutical space. Kokuma’s ingredients could integrate well into premium cosmeceutical lines, pre- and post-procedure skincare, or even serve as the foundation for new, clinically oriented brand concepts. Brands and formulators are actively looking for novel ingredients with proven efficacy and safety.
What excites me is the opportunity to help translate biotech discoveries into solutions that are clinically relevant. Kokuma’s multi-pathway approach to pigmentation, its focus on different skin types, and its commitment to strong science align well with where dermatology and aesthetics are heading today.
We are entering a period of rapid technological advancement. Biotech-driven actives and AI will continue to transform how we discover and develop skincare solutions. Energy-based devices are becoming more precise, and their integration with topical skincare will deepen. The longevity space is also expanding, with increasing focus on skin healthspan—where improving pigmentation and overall skin quality plays an important role.
As IMCAS 2026 comes to a close, Kokuma is delighted to welcome Dr. Michael Gold and looks forward to continuing to translate strong science into clinically relevant, inclusive solutions at the intersection of dermatology and biotech. shared Alexandre Jouve, CEO & Co-Founder, Kokuma
